医学
肝细胞癌
肝移植
内科学
原位肝移植
阶段(地层学)
胃肠病学
总体生存率
癌
米兰标准
移植
外科
肿瘤科
古生物学
生物
作者
Wolf O. Bechstein,Olaf Guckelberger,N. Kling,Nada Rayes,Stefan G. Tullius,H. Lobeck,Th. Vogl,Sven Jonas,P. Neuhaus
标识
DOI:10.1007/s001470050458
摘要
Recurrence-free survival (RFS) in patients with small hepatocellular carcinoma (HCC) after orthotopic liver transplantation (OLT) was analyzed. From 1988 until 1996, 725 OLTs were performed in 669 patients. In 52 adults, HCC was confirmed histologically. OLT was limited to patients with small (< 5 cm) HCC with a maximum number of three nodules. Actuarial survival for these 52 patients at 1 and 5 years is 88% and 71%. RFS was defined as time until death without recurrence time until follow up with a diagnosis of recurrence, or, in patients without recurrence, time of last follow up. Overall, the 5-year RFS was 60%. Five-year RFS was less for bilobar compared to unilobar tumors (36% vs 70%), less for stage IVa tumors (UICC) compared to stage I-III tumors (17% vs 71%), and less for multiple compared to solitary tumors (54% vs 67%). In conclusion, potential cure may be achieved in more than 50% of all transplanted patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI